Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 599-604

  Papadimitrakopoulou, Vassiliki A ^a   Lee, J Jack ^a   William Jr , William N ^a   Martin, Jack W ^a   Thomas, Margaret ^a   Kim, Edward S ^a   Khuri, Fadlo R ^a   Shin, Dong M ^a   Feng, Lei ^a   Waun, Ki Hong ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; ISOTRETINOIN; RETINOL PALMITATE; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CHEILITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPLASIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPLASIA; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH CANCER; MOUTH DISEASE; MOUTH DYSPLASIA; MOUTH HYPERPLASIA; MYALGIA; NAIL DISEASE; PATIENT COMPLIANCE; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BETA CAROTENE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TREATMENT OUTCOME; VITAMIN A; VITAMINS;

EID: 59149101065     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1850     Document Type: Article

References (20)

1. Silverman S Jr, Gorsky M, Lozada F: Oral leukoplakia and malignant transformation: A follow-up study of 257 patients. Cancer 53:563-568, 1984
2. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
3. Mayne ST, Lippman SM: Cancer Prevention: Diet and Chemopreventive: Section 4: Retinoids, Carotenoids, and Micronutrients, in Vincent T, DeVita J, Hellman S, et al (eds): Cancer: Principles & Practice of Oncology (ed 7). Philadelphia, PA, Lippincott Williams & Wilkins, 2005, pp 521-536
4. Lotan R, Xu XC, Lippman SM, et al: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332:1405-1410, 1995
5. Stich HF, Hornby AP, Mathew B, et al: Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40:93-101, 1988
6. Stich HF, Rosin MP, Hornby AP, et al: Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 42:195-199, 1988
7. Hong WK, Endicott J, Itri LM, et al: 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
8. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993
9. Papadimitrakopoulou VA, Hong WK, Lee JS, et al: Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up. J Natl Cancer Inst 89:257-258, 1997
10. Sankaranarayanan R, Mathew B, Varghese C, et al: Chemoprevention of oral leukoplakia with vitamin A and beta carotene: An assessment. Oral Oncol 33:231-236, 1997
11. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029-1035, 1994
12. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
13. Makuch R, Simon R: Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 62:1037-1040, 1978
14. Blackwelder WC: "Proving the null hypothesis" in clinical trials. Control Clin Trials 3:345-353, 1982
15. Blackwelder WC, Chang MA: Sample size graphs for "proving the null hypothesis". Control Clin Trials 5:97-105, 1984
16. Lippman SM, Lee JJ, Karp DD, et al: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93:605-618, 2001
17. Khuri FR, Lee JJ, Lippman SM, et al: Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98:441-450, 2006
18. Lee JJ, Hong WK, Hittelman WN, et al: Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 6:1702-1710, 2000
19. Lippman SM, Lee JJ: Reducing the "risk" of chemoprevention: Defining and targeting high risk-2005 AACR Cancer Res and Prevention Foundation Award Lecture. Cancer Res 66:2893-2903, 2006
20. Lippman SM, Heymach JV: The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13:4035-4041, 2007